Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    June 2018
  1. KONSTANTINOPOULOS PA, Matulonis UA
    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-18-1314.
    PubMed     Text format     Abstract available


  2. TUMIATI M, Hietanen S, Hynninen J, Pietila E, et al
    A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-17-3770.
    PubMed     Text format     Abstract available


    May 2018
  3. DENIGER DC, Pasetto A, Robbins PF, Gartner JJ, et al
    T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers.
    Clin Cancer Res. 2018 May 31. pii: 1078-0432.CCR-18-0573.
    PubMed     Text format     Abstract available


  4. GRISHAM R, Moore KN, Gordon MS, Harb W, et al
    Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0494.
    PubMed     Text format     Abstract available


  5. UUSI-KERTTULA H, Davies JA, Thompson J, Wongthida P, et al
    Ad5NULL-A20 - a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-1089.
    PubMed     Text format     Abstract available


  6. SASANO T, Mabuchi S, Kozasa K, Kuroda H, et al
    The highly metastatic nature of uterine cervical/endometrial cancer displaying tumor-related leukocytosis: clinical and preclinical investigations.
    Clin Cancer Res. 2018 May 11. pii: 1078-0432.CCR-17-2472.
    PubMed     Text format     Abstract available


  7. MATSUDA T, Leisegang M, Park JH, Ren L, et al
    Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer.
    Clin Cancer Res. 2018 May 2. pii: 1078-0432.CCR-18-0142.
    PubMed     Text format     Abstract available


    April 2018
  8. CAUMANNS JJ, Berns K, Wisman GBA, Fehrmann RSN, et al
    Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3060.
    PubMed     Text format     Abstract available


  9. DI LJ, Hao D, Liu J, Chen M, et al
    Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemo-sensitivity.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-3862.
    PubMed     Text format     Abstract available


  10. BELUR NAGARAJ A, Kovalenko O, Avelar RA, Joseph P, et al
    Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer.
    Clin Cancer Res. 2018 Apr 13. pii: 1078-0432.CCR-17-2885.
    PubMed     Text format     Abstract available


  11. ISON G, Howie LJ, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-18-0042.
    PubMed     Text format     Abstract available


  12. PULLIAM N, Fang F, Ozes AR, Tang J, et al
    An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0204.
    PubMed     Text format     Abstract available


    March 2018
  13. ZHU H, Gu X, Xia L, Zhou Y, et al
    A Novel TGF-beta Trap Blocks Chemotherapeutics-Induced TGF-beta1 Signaling and Enhances Their Anticancer Activity in Gynecological Cancers.
    Clin Cancer Res. 2018 Mar 16. pii: 1078-0432.CCR-17-3112.
    PubMed     Text format     Abstract available


  14. KALLI KR, Block MS, Kasi PM, Erskine CL, et al
    Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients.
    Clin Cancer Res. 2018 Mar 15. pii: 1078-0432.CCR-17-2499.
    PubMed     Text format     Abstract available


  15. MATEI D, Ghamande S, Roman LD, Alvarez Secord A, et al
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3055.
    PubMed     Text format     Abstract available


    February 2018
  16. HUANG YF, Wu YH, Cheng WF, Peng SL, et al
    Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-2943.
    PubMed     Text format     Abstract available


  17. LANG JD, Hendricks WPD, Orlando KA, Yin H, et al
    Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
    Clin Cancer Res. 2018 Feb 9. pii: 1078-0432.CCR-17-1928.
    PubMed     Text format     Abstract available


  18. SHAH A, Bloomquist E, Tang S, Fu W, et al
    FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-2369.
    PubMed     Text format     Abstract available


    January 2018
  19. BELLONE S, Buza N, Choi J, Zammataro L, et al
    Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-1805.
    PubMed     Text format     Abstract available


  20. HARDWICK NR, Frankel P, Ruel C, Kilpatrick J, et al
    p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2709.
    PubMed     Text format     Abstract available


    December 2017
  21. TUCKER DW, Getchell CR, McCarthy ET, Ohman AW, et al
    Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1958.
    PubMed     Text format     Abstract available


    November 2017
  22. NORQUIST BM, Brady MF, Harrell MI, Walsh T, et al
    Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-1327.
    PubMed     Text format     Abstract available


  23. PENG G, Mills GB
    Surviving ovarian cancer: an affair between defective DNA repair and RB1.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-3022.
    PubMed     Text format     Abstract available


    October 2017
  24. LABIDI-GALY SI, Olivier T, Rodrigues M, Ferraioli D, et al
    Location of mutation in BRCA2 gene and survival in patients with ovarian cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.2136.2017.
    PubMed     Text format     Abstract available


  25. BANERJI U, Dean E, Perez-Fidalgo JA, Batist G, et al
    A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.
    Clin Cancer Res. 2017 Oct 24. pii: clincanres.2260.2017.
    PubMed     Text format     Abstract available


  26. GARSED DW, Alsop K, Fereday S, Emmanuel C, et al
    Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017.
    PubMed     Text format     Abstract available


  27. KREUZINGER C, Geroldinger A, Smeets D, Braicu EI, et al
    A complex network of tumor microenvironment in human high grade serous ovarian cancer.
    Clin Cancer Res. 2017 Oct 2. pii: clincanres.1159.2017.
    PubMed     Text format     Abstract available


    September 2017
  28. COOKE SL, Ennis D, Evers L, Dowson S, et al
    The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.1789.2017.
    PubMed     Text format     Abstract available


  29. HAO D, Li J, Jia S, Meng Y, et al
    Integrated analysis reveals tubal and ovarian originated serous ovarian cancer and predicts differential therapeutic responses.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0638.2017.
    PubMed     Text format     Abstract available


  30. DEPREEUW J, Stelloo E, Osse EM, Creutzberg CL, et al
    Amplification of 1q32.1 refines the molecular classification of endometrial carcinoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0566.2017.
    PubMed     Text format     Abstract available


  31. TRABOULSI W, Sergent F, Boufettal H, Brouillet S, et al
    Antagonism of EG-VEGF receptors as targeted therapy for choriocarcinoma progression in vitro and in vivo.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0811.2017.
    PubMed     Text format     Abstract available


  32. KANG Z, Stevanovic S, Hinrichs CS, Cao L, et al
    Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping and Monitoring.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.1553.2017.
    PubMed     Text format     Abstract available


    August 2017
  33. RAGHAVAN S, Mehta P, Ward MW, Bregenzer ME, et al
    Personalized Medicine Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0133.2017.
    PubMed     Text format     Abstract available


  34. MARTINEZ E, Lesur A, Devis L, Cabrera S, et al
    Targeted proteomics identifies proteomic signatures in liquid-biopsies of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal surgical treatment.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0474.2017.
    PubMed     Text format     Abstract available


  35. LIU J, Agopiantz M, Poupon J, Wu Z, et al
    Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0861.2017.
    PubMed     Text format     Abstract available


  36. CORNELISON R, Dobbin ZC, Katre AA, Jeong DH, et al
    TARGETING RNA-POLYMERASE I IN BOTH CHEMOSENSITIVE AND CHEMORESISTANT POPULATIONS IN EPITHELIAL OVARIAN CANCER.
    Clin Cancer Res. 2017 Aug 4. pii: clincanres.0282.2017.
    PubMed     Text format     Abstract available


  37. WEIGELT B, Comino-Mendez I, de Bruijn I, Tian L, et al
    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0544.2017.
    PubMed     Text format     Abstract available


    July 2017
  38. BALASUBRAMANIAM S, Beaver JA, Horton S, Fernandes LL, et al
    FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1337.2017.
    PubMed     Text format     Abstract available


  39. MENDERES G, Bonazzoli E, Bellone S, Black JD, et al
    SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.2862.2016.
    PubMed     Text format     Abstract available


    June 2017
  40. YANG WL, Gentry-Maharaj A, Simmons AR, Ryan A, et al
    Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.0284.2017.
    PubMed     Text format     Abstract available


  41. HU Q, Hisamatsu T, Hammerle M, Cho MS, et al
    Role of platelet-derived Tgfbeta1 in the progression of ovarian cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3272.2016.
    PubMed     Text format     Abstract available


    March 2017
  42. LEE JM, Peer CJ, Yu M, Amable L, et al
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Clin Cancer Res. 2017;23:1397-1406.
    PubMed     Text format     Abstract available


  43. WANG C, Armasu SM, Kalli KR, Maurer MJ, et al
    Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.0246.2017.
    PubMed     Text format     Abstract available


  44. KRISTELEIT R, Shapiro GI, Burris HA, Oza AM, et al
    A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2796.2016.
    PubMed     Text format     Abstract available


  45. PAKISH JB, Zhang Q, Chen Z, Liang H, et al
    Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2655.2016.
    PubMed     Text format     Abstract available


  46. CUPPENS T, Annibali D, Coosemans A, Trovik J, et al
    Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
    Clin Cancer Res. 2017;23:1274-1285.
    PubMed     Text format     Abstract available


  47. APELLANIZ-RUIZ M, Tejero H, Inglada-Perez L, Sanchez-Barroso L, et al
    Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
    Clin Cancer Res. 2017;23:1227-1235.
    PubMed     Text format     Abstract available


    February 2017
  48. LHEUREUX S, Lai Z, Dougherty BA, Runswick S, et al
    Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization.
    Clin Cancer Res. 2017 Feb 21. pii: clincanres.2615.2016.
    PubMed     Text format     Abstract available


  49. NG C, Zhang Z, Lee SI, Marques HS, et al
    CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.1859.2016.
    PubMed     Text format     Abstract available


  50. KOMMOSS S, Winterhoff B, Oberg A, Konecny GE, et al
    Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
    Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016.
    PubMed     Text format     Abstract available


    January 2017
  51. SKATES SJ, Greene MH, Buys SS, Mai PL, et al
    Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2750.2015.
    PubMed     Text format     Abstract available


  52. ANDERSEN CL, Sikora MJ, Boisen MM, Ma T, et al
    Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016.
    PubMed     Text format     Abstract available


    December 2016
  53. KIM H, George E, Ragland RL, Rafail S, et al
    Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2273.2016.
    PubMed     Text format     Abstract available


  54. CHATTERJEE J, Dai W, Abd Aziz NH, Teo PY, et al
    Clinical use of programmed cell death-1 (PD-1) and its ligand (PD-L1) expression as discriminatory and predictive markers in ovarian cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2366.2016.
    PubMed     Text format     Abstract available


    November 2016
  55. NAGARAJAN P, Curry JL, Ning J, Piao J, et al
    Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016.
    PubMed     Text format     Abstract available


  56. VANDERSTICHELE A, Busschaert P, Smeets D, Landolfo C, et al
    Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses.
    Clin Cancer Res. 2016 Nov 14. pii: clincanres.1078.2016.
    PubMed     Text format     Abstract available


  57. MARTINI P, Paracchini L, Caratti G, Mello-Grand M, et al
    lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1402.2016.
    PubMed     Text format     Abstract available


    October 2016
  58. BACHMAYR-HEYDA A, Aust S, Auer K, Meier SM, et al
    Integrative Systemic and Local Metabolomics with Impact on Survival in High Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1647.2016.
    PubMed     Text format     Abstract available


  59. MONK BJ, Facciabene A, Brady WE, Aghajanian C, et al
    Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1453.2016.
    PubMed     Text format     Abstract available


  60. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.0564.2016.
    PubMed     Text format     Abstract available


  61. CHAUDARY N, Pintilie M, Jelveh S, Lindsay P, et al
    Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.1730.2016.
    PubMed     Text format     Abstract available


  62. PIULATS JM, Matias-Guiu X
    Immunotherapy in endometrial cancer: In the nick of time.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.1820.2016.
    PubMed     Text format     Abstract available


    September 2016
  63. ZHOU J, Alfraidi A, Zhang S, Santiago-O'Farrill J, et al
    A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1562.2016.
    PubMed     Text format     Abstract available


  64. FLANAGAN JM, Wilson A, Koo C, Masrour N, et al
    Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.1754.2016.
    PubMed     Text format     Abstract available


  65. AU-YEUNG G, Lang F, Azar WJ, Mitchell C, et al
    Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0620.2016.
    PubMed     Text format     Abstract available


  66. MARTIGNETTI JA, Chen Y, Camacho C, Silvers TR, et al
    INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1333.2016.
    PubMed     Text format     Abstract available


  67. LO CS, Sanii S, Kroeger DR, Milne K, et al
    Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1433.2016.
    PubMed     Text format     Abstract available


    August 2016
  68. LIU JF, Palakurthi S, Zeng Q, Zhou S, et al
    Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics.
    Clin Cancer Res. 2016 Aug 29. pii: clincanres.1237.2016.
    PubMed     Text format     Abstract available



  69. Correction: Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver.
    Clin Cancer Res. 2016;22:4272.
    PubMed     Text format    


  70. BANDERA EV, Lee VS, Rodriguez-Rodriguez L, Powell B, et al
    RACIAL/ETHNIC DISPARITIES IN OVARIAN CANCER TREATMENT AND SURVIVAL.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1119.2016.
    PubMed     Text format     Abstract available


  71. HUANG RL, Su PH, Liao YP, Wu TI, et al
    Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings.
    Clin Cancer Res. 2016 Aug 9. pii: clincanres.0863.2016.
    PubMed     Text format     Abstract available


  72. MEI Q, Li X, Zhang K, Wu Z, et al
    Genetic and methylation-induced loss of miR-181a2/181b2 within chr9q33.3 facilitate tumor growth of cervical cancer through PIK3R3/Akt/FoxO signaling pathway.
    Clin Cancer Res. 2016 Aug 8. pii: clincanres.0303.2016.
    PubMed     Text format     Abstract available


  73. SANTIN AD, Bellone S, Buza N, Choi J, et al
    Regression of chemotherapy-resistant Polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab.
    Clin Cancer Res. 2016 Aug 2. pii: clincanres.1031.2016.
    PubMed     Text format     Abstract available



  74. Correction: Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.
    Clin Cancer Res. 2016;22:3983.
    PubMed     Text format    


    July 2016
  75. PERALES-PUCHALT A, Svoronos N, Rutkowski MR, Allegrezza MJ, et al
    FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0492.2016.
    PubMed     Text format     Abstract available


  76. SKATES SJ
    EPIC Early Detection of Ovarian Cancer.
    Clin Cancer Res. 2016 Jul 14. pii: clincanres.1391.2016.
    PubMed     Text format     Abstract available


  77. CHOI YW, Kang MC, Seo YB, Namkoong H, et al
    Intravaginal administration of Fc-fused IL-7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0423.2016.
    PubMed     Text format     Abstract available


  78. HORIKAWA N, Abiko K, Matsumura N, Hamanishi J, et al
    Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0387.2016.
    PubMed     Text format     Abstract available


    June 2016
  79. MONTFORT A, Pearce OM, Maniati E, Vincent B, et al
    A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0081.2016.
    PubMed     Text format     Abstract available


  80. IKEDA Y, Park JH, Miyamoto T, Takamatsu N, et al
    T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer.
    Clin Cancer Res. 2016 Jun 22. pii: clincanres.0207.2016.
    PubMed     Text format     Abstract available


  81. BOHM S, Montfort A, Pearce OM, Topping J, et al
    Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2016;22:3025-36.
    PubMed     Text format     Abstract available


  82. HOOGSTINS CE, Tummers QR, Gaarenstroom KN, de Kroon CD, et al
    A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.
    Clin Cancer Res. 2016;22:2929-38.
    PubMed     Text format     Abstract available


  83. LI W, O'Shaughnessy JA, Hayes DF, Campone M, et al
    Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2452.2015.
    PubMed     Text format     Abstract available


    May 2016
  84. PETERS IT, Stegehuis PL, Peek R, Boer FL, et al
    Non-invasive detection of metastases and follicle density in ovarian tissue using full-field optical coherence tomography.
    Clin Cancer Res. 2016 May 16. pii: clincanres.0288.2016.
    PubMed     Text format     Abstract available


    April 2016
  85. TIPER IV, Temkin SM, Spiegel S, Goldblum SE, et al
    VEGF potentiates GD3-mediated immune suppression by human ovarian cancer cells.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2518.2015.
    PubMed     Text format     Abstract available


  86. TERRY KL, Schock H, Fortner RT, Husing A, et al
    A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort.
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.0316.2016.
    PubMed     Text format     Abstract available


    March 2016
  87. FJELDBO CS, Julin CH, Lando M, Forsberg MF, et al
    Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.
    Clin Cancer Res. 2016 Mar 24. pii: clincanres.2322.2015.
    PubMed     Text format     Abstract available


  88. DAS BC, Tyagi A, Vishnoi K, Mahata S, et al
    Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self renewal through upregulation of HES1.
    Clin Cancer Res. 2016 Mar 17. pii: clincanres.2574.2015.
    PubMed     Text format     Abstract available


    January 2016
  89. BONITO NA, Borely J, Wilhelm-Benartzi C, Ghaem-Maghami S, et al
    Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.1669.2015.
    PubMed     Text format     Abstract available


  90. KROEGER DR, Milne K, Nelson BH
    Tumor infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T cell responses, and superior prognosis in ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2762.2015.
    PubMed     Text format     Abstract available


    October 2015
  91. HEW K, Miller PC, El-Ashry D, Sun J, et al
    MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.0534.2015.
    PubMed     Text format     Abstract available


    September 2015
  92. WOUTERS MC, Komdeur FL, Workel HH, Klip HG, et al
    Treatment regimen, surgical outcome and T cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer.
    Clin Cancer Res. 2015 Sep 18. pii: clincanres.1617.2015.
    PubMed     Text format     Abstract available


    July 2015
  93. YANG JY, Werner HM, Li J, Westin SN, et al
    Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
    Clin Cancer Res. 2015 Jul 29. pii: clincanres.0104.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: